Theratechnologies Inc - Company Profile
Powered by 
All the sales intelligence you need on Theratechnologies Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Theratechnologies Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Theratechnologies Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Theratechnologies Inc (Theratechnologies) is a biopharmaceutical company that focuses on the discovery and development of drugs for people with orphan medical conditions. The company’s marketed products include Egrifta SV, which is indicated to reduce excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a CD-4 directed post-attachment HIV-1 inhibitor indicated for HIV type 1 infection in the US. Its pipeline products include Trogarzo IV slow push for HIV and Egrifta F8 for NASH HIV. The company is also developing TH 1902 for triple-negative breast cancer and TH1904 for ovarian cancer. It develops products based on peptide stabilisation technology to increase target protein resistance to enzymatic degradation. Theratechnologies is headquartered in Montreal, Quebec, Canada.
Headquarters
Canada
Address
2015 Peel Street, 11th Floor, Montreal, Quebec, H3A1T8
Website
www.theratech.com
Telephone
1 514 3367800
No of Employees
100
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$85.9M
Theratechnologies Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Egrifta- HIV-associated lipodystrophy |
| Egrifta SV- HIV-associated lipodystrophy |
| Trogarzo- HIV-1 Infection |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Ownership Changes | In September, the company was acquired by Future Pak, LLC, a contract manufacturing and packaging company. |
| 2025 | Contracts/Agreements | In July, the company entered into an agreement to be acquired by CB Biotechnology for US$254 million. |
| 2023 | Contracts/Agreements | In September, the company entered into an agreement with Marathon to modify certain conditions and terms of its credit arrangement. |
Competitor Comparison
| Key Parameters | Theratechnologies Inc | ViiV Healthcare UK Ltd | MacroGenics Inc | Xenon Pharmaceuticals Inc | Inovio Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | Canada | United Kingdom | United States of America | Canada | United States of America |
| City | Montreal | London | Rockville | Vancouver | Plymouth Meeting |
| State/Province | Quebec | England | Maryland | British Columbia | Pennsylvania |
| No. of Employees | 100 | 276 | 293 | 358 | 112 |
| Entity Type | Private | Private | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dawn Svoronos | Chairman | Executive Board | 2013 | 69 |
| Paul Levesque | Chief Executive Officer; Director; President | Executive Board | 2020 | 59 |
| Philippe Dubuc | Chief Financial Officer; Senior Vice President | Senior Management | 2016 | 56 |
| Christian Marsolais, Ph.D. | Senior Vice President; Chief Medical Officer | Senior Management | 2007 | 60 |
| Andre Dupras | Vice President - Human Resources | Senior Management | 2021 | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer